Seres Therapeutics, Inc. — Form 8-K
Filed July 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Seres announced top-line results from a 15-patient investigator-sponsored trial (MSK, NCT06801067) evaluating SER-155 for immune checkpoint inhibitor-related enterocolitis (irEC). Primary endpoint: 80% (12/15) achieved immunosuppressive-free clinical response at Day 15; 33% (5/15) achieved complete remission. Safety: no drug-related serious adverse events; well tolerated. Drug engrafted robustly with mechanistic biomarker improvements (reduced fecal calprotectin, fecal albumin) by Day 43. Company seeking partners and funding for Phase 2 in allo-HCT and next steps in irEC.
Why this rating
Encouraging early-stage data on second indication expands SER-155's addressable market (300K US ICI patients, ~$50B+ market) and validates platform. However, small n=15 open-label trial lacks placebo arm; Phase 2 remains unfunded. Relative to $71.9M market cap, validation of new indication is material but company faces severe liquidity pressure (cash runway Q1 2027, $29.8M).
See more from July 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.